IDH2 and cholangiocarcinoma: The targeted therapies that have gained FDA approval or breakthrough therapy designation for the treatment of CCA to date consist of two FGFR inhibitors, one FGFR-specific tyrosine kinase inhibitor, one IDH inhibitor, and one HER-targeting antibody.